Overview

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC/VI compared with FF/VI via ELLIPTA® inhaler in Chinese participants with inadequately controlled asthma. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline